The hypothesis that the combined effects of PARP inhibition with platinum compounds may improve platinum-based NSCLC responsiveness has been postulated, but the molecular mechanisms underlying this synergy have not been completely deciphered, at least not in the broad spectrum of NSCLC cells (Cheng et al., 2013; Stolzenburg et al., 2022). This evidence concerns the gene PARP1 and non-small cell lung carcinoma.